BLU 285 clinical program

Dr. Anthony Boral, Chief Medical Officer of Blueprint Medicines, provided an update on the clinical development of BLU-285, an investigational medicine being developed for patients with advanced GIST. The presentation included an update on results from Blueprint Medicines’ ongoing Phase 1 clinical trial of BLU-285 in patients with advanced GIST presented at the American Society of Clinical Oncology conference in Chicago, IL on Monday June 5th, 2017.